Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The buyout, announced last summer, drew the attention of federal regulators at the Federal Trade Commission, concerned that competition for ambulatory surgery services would be stifled by the merger. To appease the agency, Ascension has agreed to divest from some centers previously owned by Amsurg.
When Mayo Clinic and Microsoft announced last week that they’re partnering to develop a frontier AI model for healthcare, observers could see where Mayo’s expertise in advanced digital medicine would interest Microsoft. The Big Tech behemoth has not been coy about its healthcare ambitions.
Senate Bill 196 was signed into law by Gov. Ned Lamont a year after the state saw Prospect Medical Holdings, an investor-backed health system, fall into bankruptcy as investors extracted hundreds of millions of dollars in fees from its hospitals.
The lawsuit against Find a Black Doctor was filed by Travis Morrell, MD—a dermatologist based in Colorado—who alleges he was harmed by being excluded from the directory on the basis of race. His case has the backing of the conservative-aligned advocacy group Do No Harm.
The insurance arm of UnitedHealth Group said the shift is part of its ongoing effort to eliminate the barriers between care delivery and medical coverage. The full list of services exempt from prior authorizations includes diagnostic tests and many outpatient surgeries.
WakeMed, a three-hospital system in the North Carolina capital region of Raleigh, would become part of Advocate Health, Atrium’s parent company, if the deal goes through. Advocate is one of the largest not-for-profit health systems in the U.S.
The New Jersey-based drug developer joins AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer in offering products directly to patients at a discounted rate. Johnson & Johnson is currently listing four medications on the platform.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.
Federal regulators alleged that U.S. Anesthesia Partners—a portfolio company of Welsh, Carson, Anderson & Stowes—engaged in a “roll-up scheme” in Texas that effectively eliminated the competition. The company denies the allegations, but has agreed to undisclosed terms that would see the lawsuit resolved.